Seer to Report Third Quarter 2025 Financial Results on November 6, 2025
Seer (Nasdaq: SEER) will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a live webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will stream on the Investor section of the company website at investor.seer.bio, and an archived replay will be posted on the website after the event.
Seer (Nasdaq: SEER) comunicherà i risultati finanziari del terzo trimestre 2025 il giovedì 6 novembre 2025. La direzione organizzerà una webcast in diretta e una conference call alle 13:30 PT / 16:30 ET. L'audio in diretta sarà trasmesso nella sezione Investor del sito web dell'azienda all'indirizzo investor.seer.bio, e una replica archiviata sarà pubblicata sul sito dopo l'evento.
Seer (Nasdaq: SEER) divulgará los resultados financieros del tercer trimestre de 2025 el jueves 6 de noviembre de 2025. La dirección organizará una transmisión en vivo y una conferencia telefónica a las 1:30 p.m. PT / 4:30 p.m. ET. El audio en vivo se transmitirá en la sección de Inversores del sitio web de la compañía en investor.seer.bio, y se publicará una reproducción archivada en el sitio web después del evento.
Seer (Nasdaq: SEER)은 2025년 3분기 재무 실적을 2025년 11월 6일 목요일에 발표합니다. 경영진은 PT 1:30 / ET 4:30에 라이브 웹캐스트와 컨퍼런스 콜을 주최합니다. 라이브 오디오는 회사 웹사이트의 투자자 섹션 investor.seer.bio에서 스트리밍되며, 이벤트 후 웹사이트에 보관용 재생이 게시됩니다.
Seer (Nasdaq : SEER) annoncera les résultats financiers du troisième trimestre 2025 le jeudi 6 novembre 2025. La direction animera une webcast en direct et une conférence téléphonique à 13h30 PT / 16h30 ET. L'audio en direct sera diffusé dans la section Investisseurs du site web de l'entreprise à l'adresse investor.seer.bio, et une reproduction sous forme d'archive sera publiée sur le site après l'événement.
Seer (Nasdaq: SEER) wird die Finanzergebnisse des dritten Quartals 2025 am Donnerstag, dem 6. November 2025 vorlegen. Das Management wird einen Live-Webcast und eine Telefonkonferenz um 13:30 Uhr PT / 16:30 Uhr ET veranstalten. Live-Audio wird im Investorenbereich der Unternehmenswebsite unter investor.seer.bio gestreamt, und eine archivierte Wiedergabe wird nach der Veranstaltung auf der Website veröffentlicht.
سيير (ناسداك: SEER) ستعلن عن نتائجها المالية للربع الثالث من عام 2025 يوم الخميس 6 نوفمبر 2025. ستستضيف الإدارة بثاً مباشراً عبر الويب ومكالمة مؤتمرات في الساعة 1:30 ظهرًا بتوقيت المحيط الهادئ / 4:30 مساءً بتوقيت شرق الولايات المتحدة. سيتم بث الصوت المباشر من قسم المستثمرين في موقع الشركة على الويب investor.seer.bio، وسيتم عرض إعادة تسجيل أرشيفية على الموقع بعد الحدث.
Seer(纳斯达克股票代码:SEER) 将在 2025 年第三季度财报 于 2025 年 11 月 6 日,星期四 提交。管理层将于 太平洋时间 1:30 下午 / 东部时间 4:30 下午 举行现场直播网络广播和电话会议。现场音频将在公司网站的投资者板块 investor.seer.bio 上流式传输,活动结束后网站上将发布归档回放。
- None.
- None.
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the third quarter 2025 on Thursday, November 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Media Contact:
Consort Partners
pr@seer.bio
Investor Contact:
Carrie Mendivil
investor@seer.bio
